{"analyses":[{"ciLowerLimit":"0.25","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.47","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.34","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.24","upperLimit":"9.33","value":"7.39"},{"groupId":"OG001","lowerLimit":"1.91","upperLimit":"3.71","value":"3.55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"description":"The time from randomisation until the date of objective radiological disease progression (determined by RECIST 1.1 (soft tissue) and Prostate Cancer Working Group 3 (PCWG-3) (bone)) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anti-cancer therapy prior to progression. Progression is defined using (i) Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for soft tissue, as a \\>=20% increase in the sum of diameters of target lesions and an absolute increase of \\>=5mm taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters; (ii) Prostate Cancer Working Group 3 (PGWG-3) for bone as \\>= 2 new bone lesions on the 1st week 8 scan compared to baseline. The confirmatory scan, \\>=6 weeks later, must show \\>=2 more new bone lesions (for a total of \\>=4 new bone lesions since baseline).","dispersionType":"95% Confidence Interval","groups":[{"description":"2x150mg film-coated tablets","id":"OG000","title":"Cohort A Olaparib 300mg bd"},{"description":"either enzalutamide capsules (160 mg od) or abiraterone acetate tablets (1,000 mg od with 5 mg bid prednisone)","id":"OG001","title":"Cohort A Investigators Choice of NHA"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set","reportingStatus":"POSTED","timeFrame":"Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).","title":"Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A Only","type":"PRIMARY","unitOfMeasure":"Months"}